ORCHID PHARMA
|
|
BOM : 524372     NSE : ORCHPHARMA     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Good [Stock is Cheap] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : NA |
May 25,2022 |
Price(EOD): ₹ 284.65
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 1,161.37 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
ORCHID PHARMA | -5.5% | -24.1% | -80% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 1.3% | 31.9% |
DIVIS LABORATORIES | -16.2% | -20.1% | -9.3% |
DR REDDYS LABORATORIES | 9.6% | 4.7% | -16.9% |
CIPLA | 3.6% | 1.9% | 4.7% |
GLAND PHARMA | -11.4% | -16.5% | -9.6% |
PIRAMAL ENTERPRISES | -4.4% | -14.3% | 4.7% |
CADILA HEALTHCARE | 8.2% | 7.4% | -39.9% |
TORRENT PHARMACEUTICALS | 1.7% | -3.5% | -4.6% |
FUNDAMENTAL ANALYSIS OF ORCHID PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ORCHID PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
-
P/E Calculated based on EPS of -28.55
[ Mar2021 - Consolidated Results ] 1.78
P/B Calculated based on Book Value of 159.96
[ Mar2021 - Consolidated Results ] 2.08
P/S Calculated based on Revenues of 559.557 Cr
[ TTM - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-77% -34% 928% |
SHARE PRICE MOMENTUM OF ORCHID PHARMA
ORCHID PHARMA vs SENSEX
DEBT OF ORCHID PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
0.66 0.71 -4.28 -0.97 |
0.69 0.74 -4.59 -1.05 |
[Last Annual Data : Mar2021]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF ORCHID PHARMA
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF ORCHID PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
10.38% 75.3% 55.85% 55.85% |
48.99% 41.1% -35.43% -35.43% |
QtrlyTrend |
4 | |
Latest Qtr: Mar2022 | ||
Quarterly Result Analysis → |
ORCHID PHARMA related INDICES
You may also like the below Video Courses
FAQ about ORCHID PHARMA
Is ORCHID PHARMA good for long term investment?
As on May 25,2022, the Fundamentals of ORCHID PHARMA look Poor and hence it may not be good for long term investment ! See Financial Performance of ORCHID PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ORCHID PHARMA UnderValued or OverValued?
As on May 25,2022, ORCHID PHARMA is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of ORCHID PHARMA ?
As on May 25,2022, the Intrinsic Value of ORCHID PHARMA is Rs. 432.44 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,222.55
Fair Value [Median EV / Sales Model] : Rs. 432.44
Fair Value [Median Price / Sales Model] : Rs. 27.70
Median Fair Value of ORCHID PHARMA : Rs. 432.44
Is ORCHID PHARMA trading at a Premium or Discount?
As on May 25,2022, ORCHID PHARMA is trading at a Discount of -34% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
